CIK 0001770121
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Sana Biotechnology, Inc.
Sign in to watch- Ticker
- SANA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 831381173
- Phone
- +1 206-701-7914
- Business address
- 188 EAST BLAINE STREET, SUITE 350, SEATTLE, WA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-02-08 | NELSEN ROBERT Director | Conversion · Series B Convertible Preferred Stock | −2,343,750 | 0 | ||
| 2021-02-08 | NELSEN ROBERT Director | Conversion · Series B Convertible Preferred Stock | −2,343,750 | 0 | ||
| 2021-02-08 | Harr Steve President & CEO | Conversion | +2,031,250 | 8,173,750 | ||
| 2021-02-08 | Harr Steve President & CEO | Conversion · Series A-1 Convertible Preferred Stock | −1,075,000 | 0 | ||
| 2021-02-08 | Harr Steve President & CEO | Conversion · Series A-2 Convertible Preferred Stock | −800,000 | 0 | ||
| 2021-02-08 | Harr Steve President & CEO | Conversion · Series B Convertible Preferred Stock | −156,250 | 0 | ||
| 2021-02-08 | von Maltzahn Geoffrey Director | Conversion | +1,464,488 | 1,464,488 | ||
| 2021-02-08 | von Maltzahn Geoffrey Director | Conversion | +366,122 | 366,122 | ||
| 2021-02-08 | von Maltzahn Geoffrey Director | Conversion · Series A-2 Convertible Preferred Stock | −1,464,488 | 0 | ||
| 2021-02-08 | von Maltzahn Geoffrey Director | Conversion · Series A-2 Convertible Preferred Stock | −366,122 | 0 | ||
| 2021-02-08 | MacDonald James J. See Remarks | Conversion | +93,750 | 428,750 | ||
| 2021-02-08 | MacDonald James J. See Remarks | Conversion | +7,812 | 7,812 | ||
| 2021-02-08 | MacDonald James J. See Remarks | Conversion · Series A-1 Convertible Preferred Stock | −93,750 | 0 | ||
| 2021-02-08 | MacDonald James J. See Remarks | Conversion · Series B Convertible Preferred Stock | −7,812 | 0 | ||
| 2021-02-03 | Bilenker Joshua H. Director | Purchase | +20,000 | $25.00 | $500K | 20,000 |
| 2021-02-03 | von Maltzahn Geoffrey Director | Grant or award · Stock Option (Right to Buy) | +23,591 | 23,591 | ||
| 2021-02-03 | Bishop Hans Edgar Director | Grant or award · Stock Option (Right to Buy) | +23,591 | 23,591 | ||
| 2021-02-03 | REICIN ALISE Director | Grant or award · Stock Option (Right to Buy) | +11,795 | 11,795 | ||
| 2021-02-03 | Bilenker Joshua H. Director | Grant or award · Stock Option (Right to Buy) | +11,795 | 11,795 | ||
| 2021-02-03 | Wilderotter Mary Agnes Director | Grant or award · Stock Option (Right to Buy) | +23,591 | 23,591 |
Page 15 of 16 · 315 trades